A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Trebananib (Primary) ; Doxorubicin liposomal; Topotecan
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions
Sponsors Amgen

12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
11 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Sep 2015.
06 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Jun 2015.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com